252 related articles for article (PubMed ID: 38455044)
21. Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Honap S; Meade S; Ibraheim H; Irving PM; Jones MP; Samaan MA
Dig Dis Sci; 2022 Mar; 67(3):1018-1035. PubMed ID: 33723700
[TBL] [Abstract][Full Text] [Related]
22. Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease.
Wong U; Cross RK
Expert Opin Investig Drugs; 2019 May; 28(5):473-479. PubMed ID: 30884245
[TBL] [Abstract][Full Text] [Related]
23. Use of real-world data to assess the effectiveness of ustekinumab in treating IBD patients: a retrospective linked database study in northwest London.
Kamperidis N; Shah M; Young S; Galimov E; Sweeney S; Arebi N
Expert Opin Biol Ther; 2023; 23(12):1317-1329. PubMed ID: 38009339
[TBL] [Abstract][Full Text] [Related]
24. Mucosal IL23A expression predicts the response to Ustekinumab in inflammatory bowel disease.
Nishioka K; Ogino H; Chinen T; Ihara E; Tanaka Y; Nakamura K; Ogawa Y
J Gastroenterol; 2021 Nov; 56(11):976-987. PubMed ID: 34448069
[TBL] [Abstract][Full Text] [Related]
25. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
Gisbert JP; Chaparro M
J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
[TBL] [Abstract][Full Text] [Related]
26. Ustekinumab for skin reactions associated with anti-tumor necrosis factor-α agents in patients with inflammatory bowel diseases: A single-center retrospective study.
Ezzedine K; Visseaux L; Cadiot G; Brixi H; Bernard P; Reguiai Z
J Dermatol; 2019 Apr; 46(4):322-327. PubMed ID: 30816581
[TBL] [Abstract][Full Text] [Related]
27. Ustekinumab for children and adolescents with inflammatory bowel disease at a tertiary children's hospital in Japan.
Takeuchi I; Arai K; Kyodo R; Sato T; Tokita K; Hirano Y; Shimizu H
J Gastroenterol Hepatol; 2021 Jan; 36(1):125-130. PubMed ID: 32497325
[TBL] [Abstract][Full Text] [Related]
28. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study.
Pugliese D; Daperno M; Fiorino G; Savarino E; Mosso E; Biancone L; Testa A; Sarpi L; Cappello M; Bodini G; Caprioli F; Festa S; Laino G; Maconi G; Mazzuoli S; Mocci G; Sartini A; D'Amore A; Alivernini S; Gremese E; Armuzzi A
Dig Liver Dis; 2019 Jul; 51(7):972-977. PubMed ID: 30992173
[TBL] [Abstract][Full Text] [Related]
29. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease.
Verstockt B; Salas A; Sands BE; Abraham C; Leibovitzh H; Neurath MF; Vande Casteele N;
Nat Rev Gastroenterol Hepatol; 2023 Jul; 20(7):433-446. PubMed ID: 37069321
[TBL] [Abstract][Full Text] [Related]
30. Ustekinumab for Extra-intestinal Manifestations of Inflammatory Bowel Disease: A Systematic Literature Review.
Guillo L; D'Amico F; Danese S; Peyrin-Biroulet L
J Crohns Colitis; 2021 Jul; 15(7):1236-1243. PubMed ID: 33367674
[TBL] [Abstract][Full Text] [Related]
31. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
Whitlock SM; Enos CW; Armstrong AW; Gottlieb A; Langley RG; Lebwohl M; Merola JF; Ryan C; Siegel MP; Weinberg JM; Wu JJ; Van Voorhees AS
J Am Acad Dermatol; 2018 Feb; 78(2):383-394. PubMed ID: 29332708
[TBL] [Abstract][Full Text] [Related]
32. Safety and Efficacy of Biologic Therapies (Ustekinumab and Vedolizumab) in the Treatment of Inflammatory Bowel Disease (IBD): A Systematic Review.
Ashraf H; Bodapati A; Hanif A; Okafor DK; Katyal G; Kaur G; Khan S
Cureus; 2023 Nov; 15(11):e48338. PubMed ID: 38060699
[TBL] [Abstract][Full Text] [Related]
33. Clinical Outcomes of Ustekinumab in Inflammatory Bowel Disease.
Gara SK; Guntipalli P; Marzban S; Taqi M; Aryal V; Khan QUA; Shah SA; Akbariromani H; Salinger D; Diaz-Miret M
Cureus; 2023 Oct; 15(10):e46833. PubMed ID: 37954750
[TBL] [Abstract][Full Text] [Related]
34. Inflammatory cytokines: from discoveries to therapies in IBD.
Marafini I; Sedda S; Dinallo V; Monteleone G
Expert Opin Biol Ther; 2019 Nov; 19(11):1207-1217. PubMed ID: 31373244
[No Abstract] [Full Text] [Related]
35. Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy.
Deepak P; Loftus EV
Drug Des Devel Ther; 2016; 10():3685-3698. PubMed ID: 27956825
[TBL] [Abstract][Full Text] [Related]
36. The Long-Term Clinical Effectiveness of Ustekinumab in Antitumor Necrosis Factor-Experienced Crohn's Disease Patients.
Altuwaijri M; Hakami L; Alharbi O; Almadi M; Alshankiti S; Aljebreen A; Azzam N
Cureus; 2022 Aug; 14(8):e28536. PubMed ID: 36185868
[TBL] [Abstract][Full Text] [Related]
37. Adherence to subcutaneous biologic treatment for inflammatory bowel disease.
Ramos L; Ramos-Rodríguez J; Barreda R; Gutiérrez-Nicolás F; Carrillo-Palau M; Alonso-Abreu I; Nazco-Casariego J; Quintero E
Gastroenterol Hepatol; 2022 May; 45(5):335-341. PubMed ID: 34051312
[TBL] [Abstract][Full Text] [Related]
38. New treatment options for inflammatory bowel diseases.
Verstockt B; Ferrante M; Vermeire S; Van Assche G
J Gastroenterol; 2018 May; 53(5):585-590. PubMed ID: 29556726
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
Macaluso FS; Fries W; Viola A; Costantino G; Muscianisi M; Cappello M; Guida L; Giuffrida E; Magnano A; Pluchino D; Ferracane C; Magrì G; Di Mitri R; Mocciaro F; Privitera AC; Camilleri S; Garufi S; Renna S; Casà A; Scrivo B; Ventimiglia M; Orlando A
Expert Opin Biol Ther; 2020 Nov; 20(11):1381-1384. PubMed ID: 32981373
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study.
Hahn GD; LeBlanc JF; Golovics PA; Wetwittayakhlang P; Qatomah A; Wang A; Boodaghians L; Liu Chen Kiow J; Al Ali M; Wild G; Afif W; Bitton A; Lakatos PL; Bessissow T
World J Gastroenterol; 2022 Sep; 28(33):4823-4833. PubMed ID: 36156919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
